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ENDOTHELIN-l (ET-l), a 21 amino acid peptide with potent vasoconstrictive properties has been impli-
cated in the development of acute allograft rejection.) It is 
primarily produced by endothelial cells and its secretion, 
during acute rejection episodes, has been shown to be 
upregulated by TGFf3 and other proinflammatory cytokines 
released by graft infiltrating cells.) Additionally, ET-l has 
also been shown to facilitate proliferation of a-smooth 
muscle actin-positive (a-smA +) cells? Given that prolifer-
ation and/or accumulation of a-smA + cells is a prominent 
feature in neointimal thickening encountered in posttrans-
plant vasculopathy, it is rational to propose that ET-l may 
play an important role in the pathogenesis of this lesion. To 
test this tenet, we proceeded to block ET-receptors (both 
ETA and ET B) by bosentan (a non peptide antagonist of 
ET -1) and to study its influence on the evolvement of 
chronic rejection (CR) in an established mouse model of 
aortic allotransplantation.3 
MATERIAL AND METHODS 
Animals/Aortic Transplantation (Tx) 
Aortic grafts were transplanted across major histocompatibility 
complex-disparate C57BlIlO (H_2b) ~ C3H (H_2k) mouse strain 
combination and harvested at day 30 postimplantation for morpho-
logic and immunohistochemical analysis. While controls (n = 6) 
received PBS only, those in the study (n = 6) group were treated 
daily with bosentan (100 J.Lglanimal; iv; kindly provided by Dr Brian 
Bryzinsky, Hoffman-LaRoche, Nutley, NJ) until allograft harvest. 
In Vitro Analysis 
The titer of donor-specific alloantibodies was determined by mi-
crocytotoxicity assay. Additionally, plasma ET-1 levels were also 
ascertained by enzyme-linked immunosorbent assay (Peninsula 
Lab, Inc, Belmont, Calif). For these tests, recipient plasma was 
obtained at the time of allograft harvest (-day 30 post-Tx). 
RESULTS AND DISCUSSION 
Histopathologic examination of aorta harvested from ani-
mals treated with PBS alone revealed marked intimal 
thickening due to proliferation of a-smA + cells. Addition-
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ally. there was a variable degree of disruption of the internal 
elastic membrane with adventitial but not intimal, mono-
nuclear cell infiltration. On the contrary, allografts har-
vested from the majority of the animals treated with 
bosentan exhibited marked reduction in morphologic aber-
rations as compared to that to controls. These findings are 
consistent with earlier observations that also demonstrated 
that the use of an ET-l receptor antagonist (SB 209670) 
mitigated neointimal formation in a rat model of carotid 
artery balloon angioplasty.4 Interestingly, despite attenua-
tion of morphologic aberrations, animals treated with 
bosentan had comparable titers of anti-donor humoral 
responses as compared to that to controls. This finding 
supports our earlier contentionS that the prevailing notion 
underscoring the seminal role of alloantibodies in the 
pathogenesis of CR needs careful reconsideration. Taken 
together, these data suggest that ET-l plays an important 
role in the pathogenesis of posttransplant vasculopathy and, 
therefore, its blockade by the use of exogenous agents may 
have significant clinical utility. 
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